Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 2

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 2
---
 junior to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness, and structurally junior to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries.

The notes are listed on the Official List of The International Stock Exchange Authority, or the Exchange, under the symbol “IMMUNO30.” The Exchange is not a regulated market for the purposes of The Markets in Financial Instruments Directive (2004/39/EC). There is currently no established trading market for the notes in the United States, and we do not expect a market to develop. We do not intend to list the notes on the Nasdaq Global Select Market or any other national securities exchange or any other nationally recognized trading system in the United States.

Our ADSs are listed on the Nasdaq Global Select Market under the symbol “IMCR.” The last reported sale price of our ADSs on the Nasdaq Global Select Market on March 14, 2025 was $28.80 per ADS.

The selling securityholders will bear the costs associated with this registration of the notes and the note conversion ADSs.

Our registration of the notes and the note conversion ADSs covered by this prospectus supplement does not mean that the selling securityholders will offer or sell any of the notes or the note conversion ADSs. The notes and any the note conversion ADSs offered hereby by the selling securityholders, or their pledgees, donees, assignees, transferees or other successors-in-interest, may be sold from time to time through public or private transactions at market prices prevailing at the time of sale or at negotiated prices. The timing and amount of any sale is within the sole discretion of the selling securityholders, subject to certain restrictions. See “Plan of Distribution” for more information.

Investing in our securities involves a high degree of risk. See “**

#### Risk Factors

#### ” beginning on page S-

#### 8

#### of this prospectus supplement and page

#### 4
**of the accompanying prospectus, under similar headings in the other documents that are incorporated by reference into this prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

<div align='center'>**The date of this prospectus supplement is March 17, 2025.**</div>

TABLE OF CONTENTS